Systematic upper endoscopy concomitant with colonoscopy performed within the colorectal cancer screening program: Impact on the patients' management.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
May 2021
Historique:
received: 03 03 2020
revised: 07 07 2020
accepted: 07 07 2020
pubmed: 15 3 2021
medline: 17 12 2021
entrez: 14 3 2021
Statut: ppublish

Résumé

The French colorectal cancer screening program is based on a fecal immunochemical test, followed by colonoscopy in case of positivity. The benefit of adding a concomitant upper endoscopy to detect upper digestive lesions (precancerous or others) is still debated. Our aim was to evaluate the frequency of upper digestive lesions detected by upper endoscopy performed concomitantly with colonoscopy following a positive fecal immunochemical test, and their impact on the patients' management (i.e., surveillance, medical treatment, endoscopic or surgical procedure). Data of all the patients who consulted for a positive test between May 2016 and May 2019 in our center, and for whom concomitant upper endoscopy and colonoscopy were performed, were analyzed retrospectively. Patients with significant history of upper gastrointestinal diseases or with current gastrointestinal symptoms were excluded. One hundred patients were included [median age (min-max): 62 (50-75), men 64%]. Macroscopic and/or microscopic upper digestive lesions were found in 58 of them (58%): Helicobacter pylori infection in 17 patients, gastric precancerous lesions in 9 patients (chronic atrophic gastritis with intestinal metaplasia, n=8, low grade dysplasia, n=1), Barrett's esophagus requiring surveillance in 4 patients, and 1 duodenal adenoma with low-grade dysplasia. In 44 patients (44%), the upper endoscopy findings had an impact on patients' management, with no significant difference between the groups with positive (CRC or advanced adenoma)- or negative (any other lesions or normal) colonoscopy. A systematic upper endoscopy combined with colonoscopy for positive fecal immunochemical test could represent an efficient strategy for upper digestive lesions screening in France. Further studies are necessary to confirm these results and to evaluate cost-effectiveness of this approach.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The French colorectal cancer screening program is based on a fecal immunochemical test, followed by colonoscopy in case of positivity. The benefit of adding a concomitant upper endoscopy to detect upper digestive lesions (precancerous or others) is still debated. Our aim was to evaluate the frequency of upper digestive lesions detected by upper endoscopy performed concomitantly with colonoscopy following a positive fecal immunochemical test, and their impact on the patients' management (i.e., surveillance, medical treatment, endoscopic or surgical procedure).
METHODS METHODS
Data of all the patients who consulted for a positive test between May 2016 and May 2019 in our center, and for whom concomitant upper endoscopy and colonoscopy were performed, were analyzed retrospectively. Patients with significant history of upper gastrointestinal diseases or with current gastrointestinal symptoms were excluded.
RESULTS RESULTS
One hundred patients were included [median age (min-max): 62 (50-75), men 64%]. Macroscopic and/or microscopic upper digestive lesions were found in 58 of them (58%): Helicobacter pylori infection in 17 patients, gastric precancerous lesions in 9 patients (chronic atrophic gastritis with intestinal metaplasia, n=8, low grade dysplasia, n=1), Barrett's esophagus requiring surveillance in 4 patients, and 1 duodenal adenoma with low-grade dysplasia. In 44 patients (44%), the upper endoscopy findings had an impact on patients' management, with no significant difference between the groups with positive (CRC or advanced adenoma)- or negative (any other lesions or normal) colonoscopy.
CONCLUSION CONCLUSIONS
A systematic upper endoscopy combined with colonoscopy for positive fecal immunochemical test could represent an efficient strategy for upper digestive lesions screening in France. Further studies are necessary to confirm these results and to evaluate cost-effectiveness of this approach.

Identifiants

pubmed: 33714864
pii: S2210-7401(20)30196-0
doi: 10.1016/j.clinre.2020.07.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101501

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Orianne Planade (O)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Brigitte Dessomme (B)

Service d'Evaluation Médicale et d'Epidémiologie, Nantes University Hospital, 85 rue Saint-Jacques, Nantes 44093, France.

Nicolas Chapelle (N)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Marine Verdier (M)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Emilie Duchalais (E)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Lucille Queneherve (L)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Marc Le Rhun (M)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Emmanuel Coron (E)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Jean-Francois Mosnier (JF)

Service d'anatomie et cytologie pathologiques, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Tamara Matysiak-Budnik (T)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France. Electronic address: tamara.matysiakbudnik@chu-nantes.fr.

Yann Touchefeu (Y)

Institut des Maladies de l'appareil Digestif, Hépato-Gastroentérologie & Oncologie Digestive, Hôtel Dieu, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH